Loss of interest in usual activities, dysphoric mood, and other psychiatric signs and symptoms are defined as depression, which has a strong association with many diseases and increases mortality rates. Major Depressive Disorder (MDD) is a common psychiatric disorder. The prevalence of MDD has been determined to be 15%-25%. Recent epidemiologic studies have indicated that depression and its side effects are increasing in different societies. Drugs commonly prescribed for the management of depression include: tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase enzyme inhibitors (MAOIs). Many new drugs have recently been approved, such as Nefazodone and Buproprion. All available synthetic drugs may result in serious complications and fatal side effects. For example, Fluoxetine is an antidepressant of the SSRI group which acts by increasing the concentration of serotonin in the synaptic cleft. It causes many side effects in patients, such as sexual dysfunction, erectile dysfunction, and inability to have an orgasm. Suddenly discontinuing Fluvoxamine, a common occurrence in psychiatric patients, may result in Fluvoxamine withdrawal syndrome. Thus, more cost-effective drugs with fewer complications should be considered. Herbal medicine has recently been under consideration. Palmitic and hexadecanoic acids are a type of saturated fatty acid that has antioxidant effects, like other agents such as vitamin D. Low concentrations of palmitic acid occur naturally in plant oil and animal products. In recent years, inflammation and oxidative stress in relation to the interactions between fatty acids (FA) and depression have been considered. The level of depression has a significant association with serum palmitic acid. Also, using saturated fatty acids increases significantly the combination of saturated fatty acid with serotonergic system receptors. High fat diets cause important changes in synaptic transmission by increasing glutamate reuptake, causing synaptic effects to subside, and inhibiting mechanisms such as long-term depression in the brain. Recently, the use of palmitate in the treatment of schizophrenia has received FDA approval. The composition of palmitic acid, which is called palmitoyl ethanolamide, in combination with luteolin has been shown to have significant anti-depressant effects in mice. Studies have suggested that antioxidant drugs play a role similar to that of antidepressants. With this background and due to the lack of research on the effects of palmitic acid and its mechanism of acting, it is suggested that researchers consider the effects of palmitic acid as an anti-depressant first on animal models and then on human models.

Acknowledgments
The authors wish to thank the Baqiyatallah Student Research Committee for their financial support of this study.

Authors’ Contributions
AR and SNS contributed equally to this research.

References